At the cutting edge of protein degradation
Amphista accesses the full diversity of the cellular degradation machinery without generating ligands to specific E3 ligases. Our proprietary chemistry starts E3 agnostic. During discovery we identify target-compatible E3s via in-cell degradation screens. We have proven this approach against multiple therapeutic targets, generating potent, deep and rapid degraders which functionally engage DCAF16, DCAF11 and FBXO22.
The Targeted Glue™ advantage
Amphista is focused on exploiting the advantages of Targeted Glues™. The first technology to successfully harness multiple novel E3 ligases using drug like degraders.
Eclipsys®, a panoramic medicine discovery process
Unlike traditional therapies that transiently inhibit a single function of a protein associated with disease onset or progression, targeted protein degradation (TPD) medicines are designed to use the cell’s natural waste disposal system to selectively target and remove pathogenic proteins completely from the body.
High throughput chemistry and degradation first screening
We make custom libraries against each target then screen them in cellular degradation assays. This approach identifies active hits with novel mechanisms and has enabled us to build a pipeline of programs using novel E3 ligases.
Structurally enabled degrader optimisation
Structural information is at the heart of our process. We have generated high resolution ternary complex CryoEMs for all our lead programs.
We feed this data into custom pipelines built from cutting edge AI modelling tools to enable rational degrader design.
Cutting edge computational chemistry and chemoinformatics
Computational chemistry supercharges our workflow helping us optimise hard to predict properties in a data driven way. Virtual enumeration helps us understand and expand the available chemical space whilst machine learning predicts key properties.
Our pipeline
We are developing category-leading degrader therapeutics against important disease targets which have clear genetic or clinical relevance in patient populations of high unmet need.
